860 related articles for article (PubMed ID: 29590279)
1. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
2. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
[TBL] [Abstract][Full Text] [Related]
5. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
6. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
7. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
Malatestinic W; Nordstrom B; Wu JJ; Goldblum O; Solotkin K; Lin CY; Kistler K; Fraeman K; Johnston J; Hawley LL; Sicignano N; Araujo A
J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
10. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
11. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
12. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
14. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
17. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
19. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
20. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
